"Alzheimer's disease is a brain disorder that slowly destroys memory and thinking skills and, eventually, the ability to ...

Most pathological aggregates, called oligomers, are difficult to study with traditional methods, due to their fleeting nature and structural variability. Antibodies, known for their precise target ...

Expansion of trinucleotide repeats, such as CAG that encodes for polyglutamine, is associated with a number of neurodegenerative disorders. Expanded polyglutamine fragments form aggregates that have ...

elegans and mammalian neuronal cultures (Fonte et al, 2011). We propose that a primary mechanism of Abeta toxicity is the formation of membrane-damaging oligomers, which is blocked by the G37L ...

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Acumen Pharmaceuticals (NASDAQ: ABOS) CEO Daniel O ' Connell and Jessica Clark, ...

The live webcasts may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

Yet as the different pathological roles of distinct Aβ species have become clearer, the possibility of selectively targeting specific types of Aβ, as with ACU193’s targeting of Aβ oligomers ...

PMN310 is a humanized monoclonal antibody (mAb) designed and developed to selectively target only soluble amyloid-beta oligomers (AβOs), which are believed to be the most toxic and pathogenic form of ...

Zervimesine is an investigational oral, once-daily pill being developed for the treatment of CNS diseases, including Alzheimer disease and dementia with Lewy bodies.